Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB released its interim report for the first quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing commitment to research and development in inflammatory diseases, which is crucial for its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation through melanocortin biology.
Average Trading Volume: 187,789
Current Market Cap: SEK888M
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue